Sequence 12 from Patent US 20110319336

General Information


DRACP ID  DRACP01388

Peptide Name   Sequence 12 from Patent US 20110319336

Sequence  RLLRRLLRRLLRRLLRRLLR

Sequence Length  20

UniProt ID  P9WPT9  P59947  A6NCM1 

PubChem CID  Not available

Origin  Synthetic construct

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Hemolytic Activity  Not available

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer



Structure Information


PDB ID  Not available

Predicted Structure  DRACP01388

Helicity  Not available

Linear/Cyclic  Not available

Disulfide/Other Bond  Not available

N-terminal Modification  Not available

C-terminal Modification  Not available

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C120H232N50O21

Absent amino acids  ACDEFGHIKMNPQSTVWY

Common amino acids  LR

Mass  305056

Pl  13.45

Basic residues  10

Acidic residues  0

Hydrophobic residues  10

Net charge  10

Boman Index  -10000

Hydrophobicity  -35

Aliphatic Index  195

Half Life 
  Mammalian: 1 hour
  Yeast: 2 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  0

Amino acid distribution



Literature Information


Literature 1

Pubmed ID Not available

Title  Not available

Doi Not available

Year  Not available

Patent

Patent ID US 2011/0319336 A1

Patent Title  Selective anticancer chimeric peptide.

Other Iinformation  Granted Patent Family: 19s / 19ex; Family Jurisdictions: US, JP, EP, WO, CN; Legal Status: Active; Application No: 200913132580; Filed: Dec 3, 2009; Published: Dec 29, 2011; Earliest Priority: Dec 3, 2008; Granted: May 7, 2013

Other Published ID  CN102238965A  EP2370107A2  WO2010064207A2  WO2010064207A3 




DRACP is developed by Dr.Zheng's team.